June 6, 2018 11:55 AM EDT

Biogen, Eisai BACE drug cuts amyloid beta in the brain, but there’s no hard data to show it does anything important for cognition

John Carroll

Editor & Founder

Just after Merck $MRK research raised serious doubts about the BACE approach to tackling Alzheimer’s disease, researchers for Biogen $BIIB and Eisai are fighting …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Biogen, Eisai BACE drug cuts amyloid beta in the brain, but there’s no hard data to show it does anything important for cognition

John Carroll

Editor & Founder

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

The election is Tuesday. What’s at stake for the pharma industry?

FDA cites Mark Cuban's drug compounding center in Dallas with sterility, quality concerns

Rare disease biopharma companies weigh in on FDA's new innovation hub

'We play to win': AstraZeneca details first results for oral GLP-1 and broader obesity ambitions

Is there room for MASH drugs in a GLP-1 world?

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

Bio­gen, Ei­sai BACE drug cuts amy­loid be­ta in the brain, but there’s no hard da­ta to show it does any­thing im­por­tant for cog­ni­tion

Editor & Founder

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Biogen, Eisai BACE drug cuts amyloid beta in the brain, but there’s no hard data to show it does anything important for cognition